Journal of Digestive Cancer Reports

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지

Current Status of Systemic Therapy in Hepatocellular Carcinoma

진행성 간세포암종의 전신치료제

  • Lee, Han Ah (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine) ;
  • Seo, Yeon Seok (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine)
  • 이한아 (고려대학교 의과대학 내과학교실, 고려대학교 안암병원 소화기내과) ;
  • 서연석 (고려대학교 의과대학 내과학교실, 고려대학교 안암병원 소화기내과)
  • Received : 2020.06.07
  • Accepted : 2020.06.10
  • Published : 2020.06.30

⟨ Previous Next ⟩

Abstract

Although being one of the major causes of malignancy related death globally, hepatocellular carcinoma (HCC) has not received much attention in respect of novel drug development. Fortunately, several new drugs were found to be effective and tolerable in patients with advanced HCC from a number of phase 3 studies during the recent several years. Novel multi-targeted kinase inhibitors and immune checkpoint inhibitors were approved for clinical use, and combination strategies to maximize the potent of drugs demonstrated promising antitumor activity and safety with high response rate and improved safety profile. The increased number of available agents for HCC will contribute to change of treatment strategies and prognosis of patients with advanced HCC. Still, there is a many critical questions remain unanswered. Currently ongoing trials and future studies will provide better understanding of tumor biology and optimized criteria for patient selection and combination therapies.

Keywords

References

  1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390. https://doi.org/10.1056/NEJMoa0708857
  2. Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015;16:859-870. https://doi.org/10.1016/S1470-2045(15)00050-9
  3. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013;31:3509-3516. https://doi.org/10.1200/JCO.2012.47.3009
  4. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66. https://doi.org/10.1016/S0140-6736(16)32453-9
  5. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, et al. Lenvatinib versus sorafenib in firstline treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-1173. https://doi.org/10.1016/S0140-6736(18)30207-1
  6. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379:54-63. https://doi.org/10.1056/NEJMoa1717002
  7. Kelley RK, Mollon P, Blanc J, et al. Comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma. 2020.
  8. Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-feto-protein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20:282-296. https://doi.org/10.1016/S1470-2045(18)30937-9
  9. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non - comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-2502. https://doi.org/10.1016/S0140-6736(17)31046-2
  10. Yau T PJ, Finn RS, Cheng A-L, Mathurin P, Edeline J, et al. CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as firstline (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019;30:851-934.
  11. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a nonrandomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-952. https://doi.org/10.1016/S1470-2045(18)30351-6
  12. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, et al. Pembrolizumab as secondline therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, doubleBlind, phase III trial. J Clin Oncol 2020;38:193-202.
  13. Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 2020.
  14. Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol 2018;52:117-124. https://doi.org/10.1016/j.semcancer.2017.12.002
  15. Lee MS, RB-Y, Hsu C-H, et al. Randomized efficacy and safety reesults of atezolizumab and bevacizumab in patients with previously untreated, unresectable hepatocellular carcinoma. ESMO Annual Meeting 2019.
  16. Finn R.S. QS, Ikeda M., Galle P.R., Ducreux M., Kim T-Y, et al. Atezolizumab and bevacizumab in unresectable hepatocellular carcinoma. New England Journal of Medicine 2020;382:1894-1905. https://doi.org/10.1056/nejmoa1915745
  17. Yau T, Kang Y-K, Kim T-Y, El-Khoueiry AB, Santoro A, Sangro B, Melero I, et al. Nivolumab (NIVO)+ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. Journal of Clinical Oncology 2019;37:4012-4012. https://doi.org/10.1200/jco.2019.37.15_suppl.4012